SEC Form 10-Q filed by Zivo Bioscience Inc.

8/14/24 4:10:47 PM ET

$ZIVO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZIVO alert in real time by email

zivo_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________.

Commission File Number: 001-40449

Zivo Bioscience, Inc.

(Exact name of registrant as specified in its charter)

Nevada		87-0699977
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

21 East Long Lake Road, Ste. 100, Bloomfield Hills MI		48304
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 248-452-9866

______________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.001 per share	ZIVO	OTCQB
Warrants to purchase shares of Common Stock, par value $0.001 per share	ZIVOW	OTC Pink

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At August 9, 2024, there were 3,366,112 issued and outstanding shares of Common Stock of the registrant.

FORM 10-Q

ZIVO BIOSCIENCE, INC.

INDEX

		Page
PART I - FINANCIAL INFORMATION.

	Item 1. Condensed Financial Statements (Unaudited)	3

	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	16

	Item 3. Quantitative and Qualitative Disclosures About Market Risk.	24

	Item 4. Controls and Procedures.	24

PART II - OTHER INFORMATION.

	Item 1. Legal Proceedings.	27

	Item 1A. Risk Factors.	27

	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.	27

	Item 3. Defaults upon Senior Securities.	28

	Item 4. Mine Safety Disclosures.	28

	Item 5. Other Information.	28

	Item 6. Exhibits	29

Page 2 of 30

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	June 30,			December 31,
	2024			2023
ASSETS

CURRENT ASSETS:
Cash	$	2,466		$	274,380
Accounts receivable		-			3,735
Prepaid expenses		492,661			147,262
Total current assets		495,127			425,377
OTHER ASSETS:
Operating lease - right of use asset		48,403			98,280
Security deposit		32,058			32,058
Total other assets		80,461			130,338
TOTAL ASSETS	$	575,588		$	555,715

CURRENT LIABILITIES:
Accounts payable	$	1,093,469		$	993,090
Accounts payable – related party		79,405			172,670
Customer deposits		15,000			-
Current portion of long-term operating lease		50,920			106,342
Convertible debentures payable		240,000			240,000
Loan Payable		287,533			-
Accrued interest		101,876			100,686
Accrued liabilities – employee bonus		1,002,999			1,148,770
Total current liabilities		2,871,202			2,761,558
LONG TERM LIABILITIES:		-			-
TOTAL LIABILITIES		2,871,202			2,761,558
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY (DEFICIT):
Common stock, $0.001 par value, 25,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 3,319,032 and 2,382,356 issued and outstanding at June 30, 2024, and December 31, 2023, respectively		3,319			2,382
Additional paid-in capital		130,797,635			121,373,488
Accumulated deficit		(133,096,568	)		(123,581,714	)
Total stockholders’ equity (deficit)		(2,295,614	)		(2,205,844	)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	575,588		$	555,715

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 3 of 30

Table of Contents

ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months ended June 30, 2024			For the Three Months ended June 30, 2023			For the Six Months ended June 30, 2024			For the Six Months ended June 30, 2023
REVENUES:
Product revenue	$	-		$	4,050		$	35,720		$	4,050
Total revenues		-			4,050			35,720			4,050

COSTS OF GOODS SOLD
Product costs		-			701			23,218			701
Total cost of goods sold		-			701			23,218			701

GROSS MARGIN		-			3,349			12,502			3,349

COSTS AND EXPENSES:
General and Administrative		5,977,277			1,385,102			6,952,851			2,953,478
Research and Development		2,252,325			442,113			2,565,092			843,910


Total costs and expenses		8,229,602			1,827,215			9,517,943			3,797,388

LOSS FROM OPERATIONS		(8,229,602	)		(1,823,866	)		(9,505,441	)		(3,794,039	)

OTHER (EXPENSE):
Interest expense		(6,766	)		(31,793	)		(9,413	)		(34,762	)
Amortization of debt discount		-			(214,913	)		-			(214,913	)
Total other expense		6,766			246,706			9,413			249,675

NET LOSS	$	(8,236,368	)	$	(2,070,572	)	$	(9,514,854	)	$	(4,043,714	)

BASIC AND DILUTED LOSS PER SHARE	$	(2.78	)	$	(1.32	)	$	(3.31	)	$	(2.58	)
WEIGHTED AVERAGE BASIC AND DILUTED SHARES OUTSTANDING		2,961,606			1,569,943			2,875,631			1,569,943

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 4 of 30

Table of Contents

ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’

EQUITY (DEFICIT)

FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND JUNE 30, 2023

(UNAUDITED)

					Additional Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, March 31, 2023		1,569,943	$	1,570	$	116,034,440	$	(117,777,672	)	$	(1,741,662	)
Employee and director equity-based compensation		-		-		227,808		-			227,808
Warrants issued with related party notes		-		-		439,594		-			439,594
Net loss for the three months ended June 30, 2023		-		-		-		(2,070,572	)		(2,070,572	)
Balance, June 30, 2023		1,569,943	$	1,570	$	116,701,842	$	(119,848,244	)	$	(3,144,832	)

					Additional Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, March 31, 2024		2,789,655	$	2,790	$	122,588,510	$	(124,860,200	)	$	(2,268,900	)
Employee and director equity-based compensation		445,490		445		7,549,210		-			7,549,655
Private sales of common stock – related party		83,887		84		659,915		-			659,999
Net loss for the three months ended June 30, 2024		-		-		-		(8,236,368	)		(8,236,368	)
Balance, June 30, 2024		3,319,032	$	3,319	$	130,797,635	$	(133,096,568	)	$	(2,295,614	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 5 of 30

Table of Contents

ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’

EQUITY (DEFICIT)

FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND JUNE 30, 2023

(UNAUDITED)

					Additional Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, December 31, 2022		1,569,943	$	1,570	$	115,792,337	$	(115,804,530	)	$	(10,622	)
Employee and director equity-based compensation		-		-		469,911		-			469,911
Warrants issued with related party notes		-		-		439,594		-			439,594
Net loss for the six months ended June 30, 2023		-		-		-		(4,043,714	)		(4,043,714	)
Balance, June 30, 2023		1,569,943	$	1,570	$	116,701,842	$	(119,848,244	)	$	(3,144,832	)

					Additional Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, December 31, 2023		2,382,356	$	2,382	$	121,373,488	$	(123,581,714	)	$	(2,205,844	)
Employee and director equity-based compensation		445,490		445		7,661,314		-			7,661,759
Private sales of common stock		350,633		351		972,193		-			972,544
Private sales of common stock – related party		140,553		141		790,640		-			790,781
Net loss for the six months ended June 30, 2024		-		-		-		(9,514,854	)		(9,514,854	)
Balance, June 30, 2024		3,319,032	$	3,319	$	130,797,635	$	(133,096,568	)	$	(2,295,614	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 6 of 30

Table of Contents

ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(UNAUDITED)

	For the Six Months Ended June 30, 2024			For the Six Months Ended June 30, 2023
Cash Flows for Operating Activities:
Net loss	$	(9,514,854	)	$	(4,043,714	)
Adjustments to reconcile net loss to net cash used by operating activities:
Non cash lease expense		49,877			44,041
Employee and director equity-based compensation		7,661,759			469,911
Amortization of deferred R&D obligations participation agreements		-			(434,430	)
Amortization of debt discount		-			214,913
Changes in assets and liabilities:
Prepaid expenses		(345,399	)		(406,592	)
Customer deposits		15,000			-
Accounts receivable		3,735			(2,956	)
Accounts payable		100,379			378,655
Accounts payable – related party		(93,265	)		95,670
Lease liabilities		(55,422	)		(47,570	)
Accrued liabilities		(144,582	)		617,432
Net cash (used in) operating activities		(2,322,772	)		(3,114,640	)

Cash Flows from Investing Activities:
Net cash from by investing activities		-			-

Cash Flow from Financing Activities:
Proceeds of loans payable, other		517,560			605,600
Payments of loans payable, other		(230,027	)		(269,156	)
Proceeds of note payable, related party		-			1,000,000
Proceeds from private sales of common stock - other		972,544			-
Proceeds from private sales of common stock – related party		790,781			-
Net cash provided by financing activities		2,050,858			1,336,444

Increase (decrease) in cash		(271,914	)		(1,778,196	)
Cash at beginning of period		274,380			1,799,263
Cash at end of period	$	2,466		$	21,067

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	8,223		$	7,131
Income Taxes	$			$

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 7 of 30

Table of Contents

ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Continued)

Supplemental Disclosure of Non-Cash Investing and Financing Activities:

Six Months Ended June 30, 2024:

During the six months ended June 30, 2024, the Company exchanged $172,670 in accounts payable to related parties for 261,619 shares of common stock (see NOTE 4 - STOCKHOLDERS’ EQUITY (DEFICIT) – Equity Compensation – Restricted Stock Awards – Stock Award in Lieu of Unpaid Directors’ Fees). In addition, the Company exchanged options to buy 50,251 shares of common stock for an accrued bonus payable of $400,000 to the Company’s CEO (see NOTE 4 - STOCKHOLDERS’ EQUITY (DEFICIT) – Equity Compensation – Common Stock Options – CEO 2023 Equity Award).

Six Months Ended June 30, 2023:

During the six months ended June 30, 2023, the Company had no non-cash investing or financing transactions.

Page 8 of 30

Table of Contents

ZIVO BIOSCIENCE, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly owned subsidiaries (collectively, “we,” “our,” “us,” “ZIVO,” or the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the information set forth therein. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). The condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2023 and the notes thereto, included in its Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 15, 2024.

Going Concern

The Company has incurred net losses since inception, experienced negative cash flows from operations for the quarter ended June 30, 2024, and has an accumulated deficit of $133,096,568. The Company has historically financed its operations primarily through the issuance of common stock, warrants, and debt.

The Company expects to continue to incur operating losses and net cash outflows until such time as it generates a level of revenue to support its cost structure. There is no assurance that the Company will achieve profitable operations, and, if achieved, whether it will be sustained on a continued basis. The Company intends to fund ongoing activities by utilizing its current cash on hand and by raising additional capital through equity and/or debt financings. There can be no assurance that the Company will be successful in raising that additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditures.

These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business; no adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Stock Based Compensation

The Company accounts for stock-based compensation in accordance with FASB ASC 718, Compensation - Stock Compensation. Under the provisions of FASB ASC 718, stock-based compensation cost is estimated at the grant date based on the award’s fair value and is recognized as expense over the requisite service period. The Company, from time to time, issues restricted common stock awards or grants common stock options to its employees, consultants and board members. At the date of grant, the Company determines the fair value of the stock option award and recognizes compensation expense over the requisite service period. Issuances of restricted common stock are valued at the closing market price on the date of issuance and the fair value of any stock option or warrant awards is calculated using the Black Scholes option pricing model and employing the simplified term method as the Company does not have a historical basis to determine the expected term. The Company expenses the awards based on the vesting schedule as detailed pursuant to each individual award agreement. The Company records forfeiture of options when they occur.

Warrants

The Company accounts for warrants in accordance with FASB ASC 815 – Derivatives and Hedging. The fair value of the Company’s warrants is determined at the time of issuance using the Black Scholes option valuation model based on a market price and the remaining term of the warrant obligation. The warrants are not subject to remeasurement through the term. For the Company’s outstanding warrants, the number of shares and the exercise price shall be adjusted for standard anti-dilution events such as stock splits, combinations, reorganizations, or issue shares as part of a stock dividend. Upon a change of control, the warrant holder will have the right to receive securities, cash or other properties it would have been entitled to receive had the warrant been exercised.

Page 9 of 30

Table of Contents

NOTE 3 - DEBT

On March 5, 2024, the Company entered into a short-term unsecured loan agreement to finance a portion of the Company's directors' and officers', and employment practices liability insurance premiums. The note in the amount of $517,560 carries an 8.5% annual percentage rate and will be paid down in nine equal monthly payments of $59,562 beginning on March 10, 2024. As of June 30, 2024, a principal balance of $287,533 remains outstanding.

On February 14, 2023, the Company entered into a short-term unsecured loan agreement to finance a portion of the Company's directors' and officers', and employment practices liability insurance premiums. The note in the amount of $605,600 carried an 8.4% annual percentage rate and was paid down in nine equal monthly payments of $69,666 beginning on March 10, 2023. As of November 9, 2023, the loan was fully paid.

NOTE 4 - DEFERRED R&D OBLIGATIONS - PARTICIPATION AGREEMENTS

For the three months ended June 30, 2024 and 2023, the Company recognized $0 and $309,400, respectively, as a contra R&D expense related to personnel and third-party expenses to develop the subject technology, respectively. For the three months ended June 30, 2024 and 2023, $0 and $77,391, respectively, of this total contra R&D expense was attributed to deferred R&D obligations funded by related parties.

For the six months ended June 30, 2024 and 2023, the Company recognized $0 and $434,430, respectively, as a contra R&D expense related to personnel and third-party expenses to develop the subject technology, respectively. For the six months ended June 30, 2024 and 2023, $0 and $108,665, respectively, of this total contra R&D expense was attributed to deferred R&D obligations funded by related parties.

NOTE 5 - STOCKHOLDERS’ EQUITY (DEFICIT)

Equity Sales

During the three months ended June 30, 2024, the Company sold common stock in 9 private unregistered transactions to related parties resulting in total proceeds of $659,999 and the issuance of 83,887 shares of common stock. The Company had no sales of common stock in the three months ended June 30, 2023.

During the six months ended June 30, 2024, the Company sold common stock in 29 private unregistered transactions to investors resulting in total proceeds of $1,763,325 and the issuance of 491,186 shares of common stock. Included in the totals are 140,553 shares of common stock sold to related parties for proceeds of $790,781. The Company had no sales of common stock in the six months ended June 30, 2023.

Warrants

In the three months ended June 30, 2024 the Company issued 698 warrants to an investor under a board approved private fund raising program.

Equity Compensation

Stock Based Compensation

For the quarter ended June 30, 2024, the Company recognized expense of $7,549,655 for equity compensation to members of the Board of Directors and certain employees for restricted stock awards and option grants. The total expense amount was related to new equity grants in the present period plus equity awards from prior periods. $2,025,580 of the total expense for the quarter was related to R&D and the remaining $5,524,075 was for G&A. During the three months ended June 30, 2023, 65,268 options were granted to directors of the Company. The Company recorded compensation expense for issued grants during the three months ended June 30, 2023 of $227,808.

For the six months ended June 30, 2024, the Company expensed $7,661,759 for equity compensation to members of the Board of Directors and certain employees for restricted stock awards and option grants. The total expense amount was related to new equity grants in the present period plus equity awards from prior periods. $2,060,228 of the total expense for the quarter was related to R&D and the remaining $5,601,531 was for general and administrative expenses (G&A). During the six months ended June 30, 2023, 65,268 were granted to directors and employees of the Company. As a result of these and previous grants, the Company recorded compensation expense of $469,911 for this period.

Restricted Stock Awards

During the three months and six months ended June 30, 2024 the Board of Directors awarded 445,490 Restricted Stock Awards (RSA) to the non-employee directors of the Company under the Equity Incentive Plan for Non-Employee Directors. Of this total 18,819 RSA were issued to non-employee directors on June 11, 2024 pursuant to the Amended Non-Employee Director Compensation Policy whereby each non-employee director receives $50,000 in value of RSA calculated from the closing price of the Company’s common stock on that day. The RSA vest 25% on each of the 3 month, 6 month, and 9 month anniversaries of the award, and 25% on the day prior to the Company's 2025 annual shareholder meeting. For quarter ended June 30, 2024, the Company recognized $16,188 in directors compensation expense for these awards. The remaining 426,671 RSA were awarded by the Board to the non-employee directors of the Board under several Board approved equity compensation actions.

Director Stock Option Replacement Program

The Company had issued stock options to its non-employee directors pursuant to the 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan provides that the Board may cancel outstanding options and make a substitute grant of new options or other equity-based awards under the 2021 Plan or another equity plan of the Company (the “Director Stock Option Replacement Program”). On June 5, 2024, pursuant to the Director Stock Option Replacement Program, 127,364 shares of restricted stock were granted under the Director Equity Plan to replace all 62,451 outstanding options that were previously granted to non-employee directors under the 2021 Plan. Replacement shares were granted under the newly established Equity Incentive Plan for Non-Employee Directors. The RSA vested immediately on the date of the grant. The Company recognized $678,268 of expense in the three months ended June 30, 2024.

Page 10 of 30

Table of Contents

Stock Award Grant

On May 31, 2024, the Board granted common stock RSAs with a value of $300,000 under the Director Equity Plan to director Alison Cornell. The 37,688 RSA shares awarded were determined based on the closing price of the Company’s stock on the date of grant of $7.96 per share. The Board determined that this award to Ms. Cornell is an award for special or extraordinary services and was exempt from the annual limitation on awards to non-employee directors set forth in the Director Equity Plan.

Stock Award in Lieu of Unpaid Directors’ Fees

On May 31, 2024, the Board approved a Stock in Lieu of Unpaid Director's fees that would allow for the granting of a total of 261,619 common stock RSAs to the non-employee Board members in lieu of unpaid non-employee director service fees earned during the calendar year ending December 31, 2023. In aggregate the Company owed the three non-employee board members $172,670 in fees. These unpaid amounts were grossed up for taxes at an assumed tax rate of 45% and the number of shares was determined based on the Company’s closing stock price on December 29, 2023 of $1.20 per share.

The value of the shares granted to the non-employee directors pursuant to this exchange of stock in lieu of unpaid cash fees were exempted from the annual limitation of awards to non-employee directors set forth in the Director Equity Plan. These shares awards will be issued under the Director Equity Plan and will be subject to provisions thereof. The RSA issued under this program vested 50% immediately on the date of grant, and the remaining 50% will vest on January 1, 2025.

The Company determined the value of these awards based on the market price on the grant date of $7.96 per share and recognized $1,160,832 of expense in the three months ended June 30, 2024, for the vested portion of these awards in lieu of unpaid directors fees, and at the same time wrote off $172,670 in related party accounts payable.

No RSA was issued by the Company in the three months and six months ended June 30, 2023.

Common Stock Options

During the three months and six months ended June 30, 2024, the Company awarded options underlying 1,031,425 shares of common stock to executives and employees under the 2021 Plan. The Company recognized compensation expense for these awards and options that were previously granted to executives and employees of $5,394,367 and $5,487,178 for the three month and six month periods ended June 30, 2024, respectively.

CEO 2023 Equity Award

On June 5, 2024, the Board awarded 50,251 common stock options to the Company’s Chief Executive Officer in exchange for a prior agreed to cash payment yet unpaid in the amount of $400,000. The strike price of $7.96 was set as the closing market price on the grant date and the options vested immediately upon issuance. The Company used the Black Scholes option pricing model to determine the compensation expense of $338,815 for the award grant. The Black Scholes pricing model used the following assumptions: term of 5 years; volatility 122.46%; annual rate of dividends 0%; discount rate 4.29%.

Employee Stock Option Replacement Program

On June 5, 2024, pursuant to the Employee Stock Option Replacement Program, 981,174 common stock option shares were approved by the Board of Directors from the 2021 Plan to replace all 230,064 outstanding options that were previously granted to executive and employees under both the 2019 Plan and the 2021 Plan. Replacement shares were granted under the existing 2021 Plan. The Company used the Black Scholes option pricing model to determine the compensation expense of $5,055,552 for these award grants for the three months ending June 30, 2024. The Company determined the new options awarded under the Employee Stock Option Replacement Program to be modifications of existing awards and as such the Company will account for the awards by continuing to expense the original option awards as well as expensing the value of the new awards less the value of the old awards revalued at the conditions at the time of new awards. The Company valued the new awards using the Black Scholes pricing model with the following assumptions: option agreement term of 10 years; volatility 122.46%; annual rate of dividends 0%; discount rate 4.29%.

In the three months ending June 30, 2023, 10,878 options were granted to directors of the Company. The Company recorded compensation expense for issued grants during the three months ended June 30, 2023 and for previous grants in the amount of $227,808 for this period. During the six months ended June 30, 2023, 10,878 stock options were granted to directors of the Company. As a result of these and previous grants, the Company recorded compensation expense of $469,911 in that six month period.

The fair value of stock options was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted average assumptions:

	Three Months Ended June 30,
	2024			2023
Expected volatility		122.46	%		112.28	%
Expected dividends		-			-
Expected term	5.0-5.2 years			5.3 years
Risk free rate		4.29	%		3.88	%

Page 11 of 30

Table of Contents

	Six Months Ended June 30,
	2024			2023
Expected volatility		122.46	%		112.28	%
Expected dividends		-			-
Expected term	5.0-5.2 years			5.3 years
Risk free rate		4.29	%		3.88	%

The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions, including the expected stock price volatility. In considering the expected term of the options, the Company employs the simplified method. The Company uses this method as it does not have a history of option exercises to establish a robust estimated term based on experience. The simplified term is used for the determination of expected volatility as well as the identification of the risk-free rate.

Equity Incentive Plan for Non-Employee Directors

On May 31, 2024, the Board of Directors adopted the 2024 Equity Incentive Plan for Non-Employee Directors (the “Director Equity Plan”). Material features of the Director Equity Plan are:

	·	The maximum number of shares of common stock to be issued under the Director Equity Plan is 875,000 shares, which number will automatically increase on January 1 of each year commencing on January 1, 2025, in an amount equal to 5% of the total number of shares of the Common Stock outstanding on December 31 of the preceding year.
	·	Shares reacquired by the Company to satisfy the exercise, strike or purchase price of any award or any shares that are reacquired to satisfy a tax withholding obligation in connection with the award will be added back to the share reserve under the Director Equity Plan. The withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an award or the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an award will not be added back to the share reserve.
	·	The award of non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards is permitted.
	·	The aggregate value of all compensation granted or paid to any non-employee director with respect to any calendar year, including awards granted and cash fees paid by the Company to such non-employee director, will not exceed $750,000 in total value or, in the event such non-employee director is first appointed or elected to the Board during such calendar year, $1,000,000 in total value. These annual limits do not apply to (i) any awards made to replace stock options that were cancelled by the Board, (ii) awards made to a non-employee director for special or extraordinary services, as determined by the Board, or (iii) awards made in 2024 to compensate non-employee directors for services performed in 2023.
	·	All awards granted under the Director Equity Plan are subject to recoupment in accordance with the Company’s clawback policy.

Page 12 of 30

Table of Contents

Non-employee directors are eligible to participate in the Director Equity Plan. As of June 30, 2024, 429,510 shares remain available to be issued under the Director Equity Plan.

The foregoing description of the Director Equity Plan is qualified in its entirety by reference to the full text of the Director Equity Plan, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

2021 Equity Incentive Plan

On October 12, 2021, after approval from the stockholders at the Company’s 2021 annual meeting of stockholders, the Company adopted the 2021 Plan for the purpose of enhancing the Company’s ability to attract and retain highly qualified directors, officers, key employees and other persons and to motivate such persons to improve the business results and earnings of the Company by providing an opportunity to acquire or increase a direct proprietary interest in the operations and future success of the Company. The 2021 Plan is administered by the compensation committee of the Board who will, amongst other duties, have full power and authority to take all actions and to make all determinations required or provided for under the 2021 Plan. Pursuant to the 2021 Plan, the Company may grant options, share appreciation rights, restricted shares, restricted share units, unrestricted shares and dividend equivalent rights. The 2021 Plan has a duration of 10 years.

Subject to adjustment as described in the 2021 Plan, the aggregate number of shares of common stock available for issuance under the 2021 Plan is initially set at 1,000,000 shares; this number is automatically increased each January 1st by an amount equal to 5% of the number of common stock shares outstanding at that date, resulting in an increase in available shares under the 2021 Plan at January 1, 2024 of 119,117. On May 31, 2024, the Company’s Board of Directors amended the 2021 Plan such that the total number of shares of common stock available for issuance under the 2021 Plan would be 1,000,000 as of that date, an additional increase of 789,324 shares.

On June 5, 2024, pursuant to a proposed equity compensation exchange approved by the Board of Directors, various option awards underlying 292,515 shares of common stock were forfeited by employees and members of the Board of Directors in exchange for replacement equity awards as approved by the Board of Directors. As of June 30, 2024, 1,031,425 options have been issued under the 2021 Plan, and 261,090 shares remained available for issuance.

2019 Omnibus Long-Term Incentive Plan

Prior to the adoption of the 2021 Equity Incentive Plan, the Company maintained a 2019 Omnibus Long-Term Incentive Plan (the “2019 Plan”). Following the approval by the shareholders of the 2021 Plan, no additional awards have been or will be made under the 2019 Plan. As of June 30, 2024, all options issues under the 2019 Plan have been forfeited and no options remain outstanding. On May 31, 2024 the Company’s Board of Directors formally terminated the 2019 Plan.

Common Stock Options

A summary of the status of the Company’s options issued under the Company’s equity incentive plans is presented below. As of June 30, 2024 there is no intrinsic value in any of the Company's outstanding options as the market price of the Company's common stock is in all cases lower than the exercise price of options:

	June 30, 2024					June 30, 2023
	Number of Options			Weighted Average Exercise Price		Number of Options		Weighted Average Exercise Price
Outstanding, beginning of year		292,515		$	35.56		281,637	$	36.29
Forfeited		(292,515	)		35.56		-		-
Issued		1,031,425			7.96		10,878		16.74
Outstanding, end of period		1,031,425		$	7.96		292,515	$	35.56

Options outstanding and exercisable by price range as of June 30, 2024, were as follows:

Outstanding Options						Exercisable Options
Range of Exercise Price		Number		Average Weighted Remaining Contractual Life in Years		Range of Exercise Price		Number		Weighted Average Exercise Price
$	6.00-11.99		1,031,425		9.83	$	6.00-11.99		1,031,425	$	7.96

			1,031,425		9.83				1,031,425	$	7.96

Common Stock Warrants - Unregistered

A summary of the status of the Company’s unregistered warrants is presented below:

	June 30, 2024					June 30, 2023
	Number of Warrants			Weighted Average Exercise Price		Number of Warrants			Weighted Average Exercise Price

Outstanding, beginning of year		671,448		$	21.59		267,013		$	47.10
Issued		698			7.87		65,000			17.46
Exercised		-			-		-			-
Cancelled		-			-		-			-
Expired		(10,624	)		48.00		(99,753	)		46.20
Outstanding, end of period		661,522		$	21.15		232,260		$	39.18

Page 13 of 30

Table of Contents

Unregistered warrants outstanding and exercisable by price range as of June 30, 2024, were as follows:

Outstanding Warrants						Exercisable Warrants
Range of		Number		Average Weighted Remaining Contractual Life in Years		Exercise Price		Number		Weighted Average Exercise Price

$	6.00-11.99		698		5.00	$	6.00-11.99		698		7.87
12.00-17.99			564,376		2.43	12.00-17.99			564,376		16.88
30.00-35.99			36,800		1.92	30.00.35.99			36,800		33.00
36.00-41.99			5,309		0.24	36.00-41.99			5,309		38.40
48.00-53.99			14,026		0.42	48.00-53.99			14,026		49.07
54.00-55.99			38,543		1.20	54.00-55.99			38,543		57.60
60.00-65.99			281		1.87	60.00-65.99			281		62.40
66.00-71.99			656		1.57	66.00-71.99			656		67.20
84.00-89.99			833		0.49	84.00-89.99			833		86.40
			661,522		2.27				661,522	$	21.15

Common Stock Warrants - Registered

A summary of the status of the Company’s registered warrants is presented below:

	June 30, 2024				June 30, 2023
	Number of Registered Warrants		Weighted Average Exercise Price		Number of Registered Warrants		Weighted Average Exercise Price
Outstanding, beginning of year		495,917	$	33.00		495,917	$	33.00
Issued		-		-		-		-
Exercised		-		-		-		-
Cancelled		-		-		-		-
Expired		-		-		-		-
Outstanding, end of period		495,917	$	33.00		495,917	$	33.00

Registered warrants outstanding and exercisable by price range as of June 30, 2024, were as follows:

Outstanding Registered Warrants						Exercisable Registered Warrants
Exercise Price		Number		Average Weighted Remaining Contractual Life in Years		Exercise Price		Number		Weighted Average Exercise Price

$	33.00		495,917		1.93	$	33.00		495,917		33.00

Page 14 of 30

Table of Contents

NOTE 6 - COMMITMENTS AND CONTINGENCIES

Employment Agreements

At June 30, 2024, the Company had compensation agreements with its President / Chief Executive Officer, and Chief Financial Officer.

Legal Contingencies

The Company may become a party to litigation in the normal course of business. In the opinion of management, there are no pending legal matters involving the Company that would have a material adverse effect upon the Company’s financial condition, results of operation or cash flows.

NOTE 7 - INCOME TAX

The Company and its subsidiaries are subject to US federal and state income taxes. Income tax expense is the total of the current year income tax due or refundable and the change in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of Management, it is more likely than not that some portion, or all, of the deferred tax asset will not be realized. The Company does not expect to realize the net deferred tax asset and as such has recorded a full valuation allowance.

Income tax expense for the three months and six months ended June 30, 2024 and 2023 is based on the estimated annual effective tax rate. Based on the Company’s effective tax rate and full valuation allocation, tax expense is expected to be $0 for 2024.

NOTE 8 - SUBSEQUENT EVENTS

The Company sold and issued common stock and warrants in three private transactions since July 1, 2024, the first for 20,000 common shares and 2,000 warrant shares to an investor for proceeds of $156,800, the second for 2,080 common shares and 208 warrant shares to a related party for $16,752 in proceeds, and the third of 25,000 common shares and 2,500 warrant shares to an investor for $201,250 in proceeds.

Page 15 of 30

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements contained in this report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements regarding:

·	our ability to raise the funds we need to continue our operations;
·	our goal to generate revenues and become profitable;
·	regulation of our product;
·	market acceptance of our product and derivatives thereof;
·	the results of current and future testing of our product;
·	the anticipated performance and benefits of our product;
·	the ability to generate licensing fees; and
·	our financial condition or results of operations.

In some cases, you can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “projects”, “predicts”, “potential”, “likely” and similar expressions intended to identify forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this report to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. We qualify all of our forward-looking statements by these cautionary statements.

You should refer to the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements will prove to be accurate. No forward-looking statement is a guarantee of future performance.

Overview:

We are a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health.

Biotech - ZIVO Product Candidates

ZIVO is developing bioactive compounds derived from its proprietary algal culture, targeting human and animal diseases, such as poultry coccidiosis, bovine mastitis, human cholesterol, and canine osteoarthritis. As part of its therapeutic strategy, ZIVO will continue to seek strategic partners for late stage development, regulatory preparation and commercialization of its products in key global markets.

Review of isolated active materials derived from our proprietary algal culture and their potential treatment applications led us to identify a product candidate for treating coccidiosis in broiler chickens as the best option for most rapidly generating significant revenue because coccidiosis is a global poultry industry issue, and because the clinical testing cycle for chickens is shorter than for other species. Most of the global animal health companies have products for the coccidiosis market; however, they are mostly antibiotic- or ionophore-based with essentially no new technology having been introduced in the last 60 years.

Agtech - ZIVO’s Algal Biomass

ZIVO’s algal biomass is currently produced in Peru. ZIVO’s algal biomass contains Vitamin A, protein, iron, important fatty acids, non-starch polysaccharides and other micronutrients that position the product as a viable functional food ingredient and nutritional enhancement for human and animal use and as a viable functional ingredient for skin care products.

Through our direction and technology, a site in Peru has been successful in consistently producing our proprietary algae. Our team has been working toward building commercial-scale algae ponds using a ZIVO proprietary design, and we are in the middle of a project to grow our algae in a penultimate scale pond. Once we are successful at this scale, we plan to invest in full commercial-scale ponds and product processing equipment.

The Company currently has contracts for the sale and production of its algal biomass. ZIVO has engaged an independent distributor, ZWorldwide, Inc., who has begun to sell the product, branded ZivolifeTM, with an initial focus on the North American green powder food market with the product being grown in Peru.

Page 16 of 30

Table of Contents

Additional Indications

Pending additional funding, ZIVO may also pursue the following indications:

Biotech:

	o	Bovine Mastitis: ZIVO is developing a treatment for bovine mastitis derived from its proprietary algal culture and the bioactive agents contained within.

	o	Canine Joint Health: Studies have indicated the potential of a chondroprotective property when a compound fraction was introduced into ex vivo canine joint tissues.

	o	Human Immune Modulation: Early human immune cell in vitro and in vivo studies have indicated that one of the isolated and characterized biologically active molecules in the Company’s portfolio may serve as an immune modulator with potential application in multiple disease situations.

Agtech:

	o	Companion Animal Food Ingredient: The self-affirmed GRAS process was completed for ZIVO algal biomass in late 2018 and updated in early 2023 to validate its suitability for human consumption as an ingredient in foods and beverages. We plan to leverage this work into viable food and nutritional supplements for companion animals.

	o	Skin Health: ZIVO is developing its algal biomass as a skin health ingredient, the Company has engaged in some limited topical skin product testing started in the third quarter of 2020, and we plan to perform clinical efficacy claim studies planned for ingestible and topical products.

Page 17 of 30

Table of Contents

Results of Operations for the three months ended June 30, 2024 and 2023

The following table summarizes ZIVO’s operating results for the periods indicated:

	Quarter ended June 30,
	2024			2023
Total revenue:	$	-		$	4,050
Total cost of goods sold		-			701
Gross margin		-			3,349
Costs and expenses:
Research and development		2,252,325			442,113
General and administrative		5,977,277			1,385,102
Total costs and expenses		8,229,602			1,827,215
Loss from operations		(8,229,602	)		(1,823,866	)
Other (expense):
Total other expense		(6,766	)		(246,706	)
Net loss	$	(8,236,368	)	$	(2,070,572	)

Revenue

During the three months ended June 30, 2024, the Company recorded no commercial revenue relating to sales of the Company’s dried algal biomass product as a human food or food ingredient. This is a $4,050 reduction from the same period last year. The $4,050 decrease is the result of no product volume sold in the three months ended June 30, 2024. The Company experienced no product volume sold in the three months ended June 30, 2024 as our distribution partner was making material changes to their inventory, warehouse and shipping processes.

Costs of Goods Sold

Cost of goods sold for the quarter ended June 30, 2024 was $0. This is $700 lower than the same period last year, attributable to product volume as no product was shipped in this the three months ending June 30, 2024.

General and Administrative Expenses

General and administrative expenses were approximately $6.0 million for the three months ended June 30, 2024, as compared to approximately $1.4 million for the comparable prior year period. The increase of approximately $4.6 million in general and administrative expense during 2024 is due to an increase in labor related expenses of $2.8 million, an increase in professional services of $1.9 million, partially offset by a $70,000 decrease in other overhead costs. The $2.8 million increase in labor related costs is explained by a $3.2 million increase in non-cash equity related compensation awarded by the Board of Directors to certain Company employees; which was partially offset by a $400,000 reduction in bonus expense due an agreement between the Board and the CEO to exchange an unpaid cash bonus for common stock options. The $1.9 million year over year increase in professional services expense is primarily due to equity compensation awarded to the Board of Directors totaling approximately $2.0 million, which was partially offset by lower legal and consulting expenses of approximately $100,000. The $70,000 decrease in other overhead spending is attributable mostly to lower insurance, filing, and listing fees.

Research and Development Expenses

For the three months ended June 30, 2024, the Company incurred approximately $2.3 million in research and development expenses, as compared to approximately $440,000 for the comparable period in 2023. In the quarter ended June 30, 2023, the Company’s research and development spending included approximately $309,400 of amortization of deferred research and development obligations for the participation agreements; there was no amortization of deferred research and development in the three months ending June 30, 2024.

Page 18 of 30

Table of Contents

In the quarter ended June 30, 2024, excluding this amortization, the Company had gross research and development spending of approximately $2.3 million; a $1.5 million increase in spending from the second quarter of 2023. Of these costs in the second quarter of 2024, $2.2 million was attributable to labor and other internal research and development costs, an increase of approximately $1.9 million from the comparable prior year. The increase is entirely the result of higher non-cash equity compensation related costs. Third party research and development spending of approximately $10,000 was $420,000 lower than the comparable prior year period due to a pause in third party research studies.

	Quarter ended June 30,		Quarter ended June 30,
	2024		2023
Labor and other internal expenses	$	2,245,261	$	326,755
External research expenses		7,064		424,758
Total gross R&D expenses		2,252,325		751,513
Less contra-expense for amortization of deferred R&D obligation - participation agreements		-		(309,400	)
Research and development	$	2,252,325	$	442,113

Results of Operations for the six months ended June 30, 2024 and 2023

The following table summarizes ZIVO’s operating results for the periods indicated:

	Six Months ended June 30,
	2024			2023
Total revenue:	$	35,720		$	4,050
Total costs of goods sold		23,218			701
Gross margin		12,502			3,349
Costs and expenses:
Research and development		2,565,092			843,910
General and administrative		6,952,851			2,953,478
Total costs and expenses		9,517,943			3,797,388
Loss from operations		(9,505,441	)		(3,794,039	)
Other (expense):
Total other expense		(9,413	)		(249,675	)
Net loss	$	(9,514,854	)	$	(4,043,714	)

Revenue

In the six months ended on June 30, 2024 the Company recorded commercial revenue of $35,720 for sales of the Company’s dried algal biomass product as a human food or food ingredient. The $35,720 for the six months ending June 30, 2024 is an increase over the $4,050 in revenue in the same six month period ended June 30, 2023. The approximately $30,000 increase is due to higher sales volumes.

Costs of Goods Sold

Cost of goods sold for the six months ended June 30, 2024 was $23,218. This is approximately $22,000 higher than the same period last year, explained by the increase in sales volume.

General and Administrative Expenses

General and administrative expenses were approximately $7.0 million for the six months ended June 30, 2024, an increase from the $3.0 million in the comparable prior year period. The increase of approximately $4.0 million in general and administrative expense during 2024 is explained by higher labor related costs of approximately $2.8 million and $1.3 million of professional services, partially offset by a reduction in other overhead of $120,000. The $2.8 million increase in labor related expenses is attributable to an increase in non-cash equity related employee compensation of $3.2 million partially offset by a reductions in bonus expense of $400,000. Professional services expense increases of $1.3 million is due directors’ compensation increases of $1.9 million partially offset by lower legal ($420,000), accounting ($125,000) and consultants ($50,000) that were elevated in the six months ending June 30, 2023 as the Company undertook funding activities. The approximately $120,000 reduction in other overhead is attributable to a $40,000 reduction in insurance expense, lower filing, and listing costs of $45,000, and a significant reduction in travel and entertainment expense of $25,000.

Page 19 of 30

Table of Contents

Research and Development Expenses

For the six months ended June 30, 2024, the Company incurred approximately $2.6 million in research and development expenses, as compared to approximately $840,000 in the comparable period in 2023. In the six months ended June 30, 2024, the Company’s research and development spending included no amortization of deferred research and development, in the comparable prior year period approximately $430,000 of amortization of deferred research and development obligations for the participation agreements.

In the six months ended June 30, 2024, excluding this amortization, the Company had gross research and development spending of approximately $2.6 million; a $1.3 million increase in spending from the first half of 2023. Of these costs in the first half of 2024, approximately $2.5 million was related to labor and other internal lab costs, an increase of approximately $1.9 million from the comparable prior year, primarily attributable to an increase in non-cash compensation of $1.9 million. Third party research and development spending of approximately $20,000 was $590,000 lower than the comparable prior year period due to a pause in third party research studies.

	Six months ended June 30,		Six months ended June 30,
	2024		2023
Labor and other internal expenses	$	2,543,176	$	664,667
External research expenses		21,916		613,673
Total gross R&D expenses		2,565,092		1,278,340
Less contra-expense for amortization of deferred R&D obligation - participation agreements		-		(434,430	)
Research and development	$	2,565,092	$	843,910

Capital Resources

As of June 30, 2024, ZIVO’s principal source of liquidity consisted of cash of $2,466. The Company expects to continue to incur significant expenses and increasing operating and net losses for the foreseeable future until and unless we generate an adequate level of revenue from potential commercial sales to cover expenses. The sources of cash to date have been limited proceeds from the issuance of notes with warrants, common stock with and without warrants and unsecured loans. In the six months ended June 30, 2024, the Company raised approximately $1.8 million from direct sale of 491,186 shares of common stock in private transactions to qualified individuals. The shares were priced at the prior day’s closing price of the common stock on the OTCQB market.

June 2023 Registered Direct Offering and Private Placement

On June 30, 2023, the Company sold 171,666 shares of common stock, par value $0.001 per share, at an offering price of $16.02 per share, and pre-funded warrants to purchase up to an aggregate of 78,021 shares of Common Stock at an offering price of $16.0194 per pre-funded warrant, to a single institutional investor. In a concurrent private placement, the Company also directly sold to the purchaser Series A Common Warrants to purchase up to an aggregate of 249,688 shares of common stock, at an exercise price of $16.80 per share and Series B Common Warrants to purchase up to an aggregate of 249,688 shares of Common Stock, at an exercise price of $16.80 per share. The Series A Common Warrants are immediately exercisable, subject to a beneficial ownership limitation of the holder provided in the Series A Common Warrants, at any time on or after the date of issuance and will expire two years from the initial exercise date. The Series B Common Warrants are immediately exercisable, subject to a beneficial ownership limitation of the holder provided in the Series B Common Warrants, at any time on or after the date of issuance and will expire five years from the initial exercise date. The gross proceeds to the Company from the registered direct offering and concurrent private placement were approximately $4,000,000.00 (before deducting the placement agent’s fees and other estimated offering expenses payable by the Company).

2023 and 2024 Private Direct Offerings

In November 2023, the Board of Directors approved a direct private offering to raise capital to fund the Company’s operations, the 2023 Private Offering. The funding program targeted a small number of existing investors and offered common stock for to be purchased at the market price as reported on the OTCQB exchange. Between December 5, 2023 and June 13, 2024 the Company sold 1,047,214 shares of stock in 37 separate transactions for proceeds of $2,348,325, an average of $2.24 per share. Of this total, related parties participated in 15 transactions for the purchase of 571,257 shares of stock yielding proceeds to the Company of $1,220,781, an average of $2.14 per share. None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering.

On June 10, 2024, the Board of Directors appointed a pricing committee of the board to establish an enhanced private direct offering which resulted in the 2024 Private Offering. This funding program has a stock price based on the prior 30-day average closing price as reported on the OTCQB, and each investor will receive warrants to purchase common stock at a rate of 1 warrant share for every 10 common shares purchased. The warrants have the same strike price as the common stock for each purchase agreement, have a life of five years, and have provisions to allow for a cashless exercise. Since June 28, 2024, the Company has entered into 4 transactions under the 2024 Private Offering, resulting in the sale of 54,068 shares of commons stock and 5,406 warrant shares for proceeds of $429,802, an average of $7.95 per share. Two of these transactions were with related parties for 9,068 shares of common stock, 906 warrant shares, resulting in proceeds of $71,752. None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering.

Page 20 of 30

Table of Contents

Participation Agreements

From April 13, 2020, through May 14, 2021, the Company entered into twenty-one License Co-Development Participation Agreements (the “Participation Agreements”) with certain accredited investors (“Participants”) for an aggregate of $2,985,000 in proceeds. The Participation Agreements provide for the issuance of warrants to such Participants and allows the Participants to participate in the fees (the “Fees”) from licensing or selling bioactive ingredients or molecules derived from ZIVO’s algae cultures. Specifically, ZIVO has agreed to provide to the Participants a 44.775% “Revenue Share” of all license fees generated by ZIVO from any licensee.

The Participation Agreements allow the Company the option to buy back the right, title and interest in the Revenue Share for an amount equal to the amount funded plus a forty percent (40%) premium, if the option is exercised less than 18 months following execution, and for either forty (40%) or fifty percent (50%) if the option is exercised more than 18 months following execution. Pursuant to the terms of twelve of the Participation Agreements, the Company may not exercise its option until it has paid the Participants a revenue share equal to a minimum of thirty percent (30%) of the amount such Participant’s total payment amount. Pursuant to the terms of the one of the Participation Agreements, the Company may not exercise its option until it has paid the Participant a revenue share equal to a minimum of one hundred forty percent (140%) of the amount such Participant’s total payment amount. Five of the Participation Agreements have no minimum threshold payment. Once this minimum threshold is met, the Company may exercise its option by delivering written notice to a Participant of its intent to exercise the option, along with repayment terms of the amount funded, which may be paid, in the Company’s sole discretion, in one lump sum or in four (4) equal quarterly payments. If the Company does not make such quarterly payments timely for any quarter, then the Company shall pay the prorate Revenue Share amount, retroactive on the entire remaining balance owed, that would have been earned during such quarter until the default payments have been made and the payment schedule is no longer in default.

Funding Requirements

Management has noted the existence of substantial doubt about our ability to continue as a going concern. Our existing cash will not be sufficient to fund our operating expenses through at least twelve months from the date of this filing. To continue to fund operations, we will need to secure additional funding through public or private equity or debt financings, through collaborations or partnerships with other companies or other sources. We may not be able to raise additional capital on terms acceptable to us, or at all. Any failure to raise capital when needed could compromise our ability to execute on our business plan. If we are unable to raise additional funds, or if our anticipated operating results are not achieved, we believe planned expenditures may need to be reduced in order to extend the time period that existing resources can fund our operations. If we are unable to obtain the necessary capital, it may have a material adverse effect on our operations and the development of our technology, or we may have to cease operations altogether.

Our material cash requirements relate to the funding of our ongoing product development and for payment of significant levels of accounts payable and accrued executive and employee bonuses. The development of our product candidates is subject to numerous uncertainties, and we could use our cash resources sooner than we expect. Additionally, the process of development is costly, and the timing of progress in pre-clinical tests and clinical trials is uncertain. Our ability to successfully transition to profitability will be dependent upon achieving further regulatory approvals and achieving a level of product sales adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

Statement of Cash Flows

Cash Flows from Operating Activities. During the six months ended June 30, 2024, our operating activities used $2.3 million in cash, a decrease of cash used of approximately $800,000 from the comparable prior year period when the Company used approximately $3.1 million for operating activities. After adjusting the comparison period’s net income for non-cash expenses including equity-based compensation and amortization of lease liabilities, the Company incurred approximately $1.9 million less of additional cash net loss than in the comparable prior year period. In addition, for the six months ended June 30, 2024, the Company generated about $1.1 million less cash than the prior year period through decreases in working capital accounts.

Page 21 of 30

Table of Contents

Cash Flows from Investing Activities. During the six months ended June 30, 2024 and 2023, there were no investing activities.

Cash Flows from Financing Activities. During the six months ended June 30, 2024, our financing activities generated approximately $2.1 million, an increase of approximately $800,000 from the comparable prior year period when the Company generated approximately $1.3 million from financing activities. In the six months ended June 30, 2024, the Company received net proceeds of $1.8 million from direct sales of common equity to investors, and raised a net $300,000 from proceeds of a short term financing agreement. In the six months ending June 30, 2023, the Company received proceeds of $1.0 million from a term loan provided by a related party to the Company, and raised a net $300,000 from proceeds of a short term financing agreement.

	Six months ended June 30,
	2024			2023
Net cash provided by (used in):
Operating activities	$	(2,322,772	)	$	(3,114,640	)
Investing activities		-			-
Financing activities		2,050,858			1,336,444
Net increase (decrease) in Cash	$	(271,914	)	$	(1,778,196	)

We estimate that we would require approximately $6.0 million in cash over the next 12 months in order to fund our basic operations, excluding our research and development initiatives. Based on this cash requirement, we have a near term need for additional funding to continue to develop our products and intellectual property. Historically, we have had substantial difficulty raising funds from external sources. If we are unable to raise the required capital, we will be forced to curtail our business operations, including our research and development activities.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our financial statements prospectively from the date of the change in estimate.

For a discussion of our critical accounting estimates, please read Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 15, 2024. There have been no material changes to the critical accounting estimates previously disclosed in our Annual Report on Form 10-K.

Page 23 of 30

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable for smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that information required to be disclosed is accumulated and communicated to management, including our principal executive and financial officers, to allow timely decisions regarding disclosure. The Chief Executive Officer, as our principal executive officer, and the Chief Financial Officer, as our principal financial and accounting officer, have reviewed the effectiveness of our disclosure controls and procedures and, based on their evaluation, have concluded that the disclosure controls and procedures were not effective as the material weaknesses identified as of December 31, 2023 in our Annual Report on Form 10-K and described below, continue to exist as of June 30, 2024.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not detect or prevent misstatements. Also, projections of any evaluation of the effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management utilized the criteria established in the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) to conduct an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2023. As previously reported, we identified material weaknesses that continued to exist at December 31, 2023. In addition, in connection with the audit of our consolidated financial statements for the year ended December 31, 2023, we identified additional material weaknesses in internal control over financial reporting, as described below. The material weakness has not been remediated as of June 30, 2024.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Page 24 of 30

Table of Contents

Material Weaknesses in Internal Control Over Financial Reporting

Management has determined that the Company had the following material weaknesses in its internal control over financial reporting:

Control Environment, Risk Assessment, and Monitoring

As previously discussed in our Annual Report for the year ended December 31, 2023, management had concluded that our internal control over financial reporting was not effective as of December 31, 2023, due to: (i) lack of structure and responsibility, insufficient number of qualified resources, and inadequate oversight and accountability over the performance of controls, (ii) ineffective identification and assessment or risks impacting internal control over financial reporting, and (iii) ineffective evaluation and determination as to whether the components of internal control were present and functioning.

Control Activities and Information and Communication

These material weaknesses contributed to the following additional material weaknesses within certain business processes and the information technology environment:

·	Management did not design and maintain appropriate information technology general controls in the areas of user access, vendor management controls, and segregation of duties, including controls over the recording and review of journal entries, related to certain information technology systems that support the Company’s financial reporting process.

·	Management did not design, implement, and retain appropriate documentation of formal accounting policies, procedures, and controls across substantially all of the company's business processes over; (i) the financial reporting process, including management review controls over key disclosures and financial statement support schedules, (ii) the monthly financial close process, including journal entries and account reconciliations and (iii) the completeness and accuracy of information used by control owners in the operation of certain controls, to achieve timely, complete, accurate financial accounting, reporting.

·	Management did not design and implement controls over the accounting, classification, and application of United States Generally Accounting Principles (“US GAAP”) relating to income taxes, stock-based compensation, and deferred research and development obligations - participation agreements accounting. Specifically:

	·	Management did not identify controls over the review of the tax provision, including the valuation analysis related to deferred tax assets, considerations for uncertain tax positions, the preparation of the income tax footnote and required disclosures and selecting and applying accounting policies;

	·	Management did not identify controls over the accounting and classification of deferred research and development obligations - participation agreements; and

	·	Management did not identify controls over the valuation of stock-based compensation for option awards to employees and members of the board of directors.

Based on the assessment and identification of the material weaknesses described above, management has concluded that, as of June 30, 2024, our internal control over financial reporting was not effective and could lead to a material misstatement of account balances or disclosures. Accordingly, management has concluded that these control deficiencies constitute material weaknesses.

However, after giving full consideration to these material weaknesses, and the additional analyses and other procedures that we performed to ensure that our consolidated financial statements included in this Quarterly Report on Form 10-Q were prepared in accordance with U.S. GAAP, our management has concluded that our consolidated financial statements present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. GAAP.

Remediation Plans

Management has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:

·	Developing a training program and educating control owners concerning the principles of the Internal Control - Integrated Framework (2013) issued by COSO;

·	Implementing a risk assessment process by which management identifies risks of misstatement related to all account balances;

·	Developing internal controls documentation, including comprehensive accounting policies and procedures over financial processes and related disclosures;

Page 25 of 30

Table of Contents

·	Enhancing policies and procedures to retain adequate documentary evidence for certain management review controls over certain business processes including precision of review and evidence of review procedures performed to demonstrate effective operation of such controls;

·	Engaging outside resources for complex accounting matters and drafting and retaining position papers for all complex, non-recurring transactions;

·	Developing monitoring activities and protocols that will allow us to timely assess the design and the operating effectiveness of controls over financial reporting and make necessary changes to the design of controls, if any;

·	Segregating key functions within our financial and information technology processes supporting our internal controls over financial reporting;

·	Reassessing and formalizing the design of certain accounting and information technology policies relating to security and change management controls, including user access reviews, including assessing the need for implementing a more robust information technology system; and

·	Continuing to enhance and formalize our accounting, business operations, and information technology policies, procedures, and controls to achieve complete, accurate, and timely financial accounting, reporting and disclosures.

Changes in Internal Control Over Financial Reporting

Except as discussed above, there was no other change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ending June 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Page 26 of 30

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be subject to litigation and claims arising in the ordinary course of business.

In our opinion, we are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings that are material to our financial condition, either individually or in the aggregate.

Item 1A. Risk Factors

There have been no material changes in our risk factors previously disclosed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023. You should carefully consider the risks and uncertainties described therein.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following is a summary of all securities that we have issued beginning on April 1, 2024 without registration under the Securities Act of 1933, as amended (the “Securities Act”):

Common Stock:

Name	Form	Date	Amount Received	Common Stock Shares
Strome Mezzanine Fund II LP	Purchase of Common Stock	07-Jul-24	$156,800.00	20,000
Strome Mezzanine Fund II LP	Purchase of Common Stock	24-Jul-24	$201,250.00	25,000

Common Stock – Related Parties:

Name	Form	Date	Amount Received	Common Stock Shares
HEP Investments, LLC	Purchase of Common Stock	2-Apr-24	$100,000.00	13,333
HEP Investments, LLC	Purchase of Common Stock	26-Apr-24	$100,000.00	12,500
HEP Investments, LLC	Purchase of Common Stock	7-May-24	$130,000.00	16,455
HEP Investments, LLC	Purchase of Common Stock	14-May-24	$60,000.00	7,662
HEP Investments, LLC	Purchase of Common Stock	30-May-24	$100,000.00	12,531
Chris Maggiore	Purchase of Common Stock	12-Jun-24	$29,999.08	3,764
HEP Investments, LLC	Purchase of Common Stock	13-Jun-24	$35,000.00	4,380
HEP Investments, LLC	Purchase of Common Stock	12-Jun-24	$50,000.00	6,274
HEP Investments, LLC	Purchase of Common Stock	28-Jun-24	$55,000.00	6,988
Chris Maggiore	Purchase of Common Stock	24-Jul-24	$16,751.64	2,080

None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe the offers, sales and issuances of the above securities were exempt from registration under the Securities Act by virtue of Section 4(a)(2) of the Securities Act because the issuance of securities to the recipients did not involve a public offering, or in reliance on Rule 701 because the transactions were pursuant to compensatory benefit plans or contracts relating to compensation as provided under such rule. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about Zivo. The sales of these securities were made without any general solicitation or advertising.

Page 27 of 30

Table of Contents

Item 3. Defaults upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Page 28 of 30

Table of Contents

Item 6. Exhibits

Exhibit Number		Description

3.1		Articles of Incorporation of the Registrant as amended (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q filed on August 22, 2011)

3.2		Certificate of Amendment to Articles of Incorporation dated October 16, 2014 (incorporated by reference to Exhibit 3.12 to the Registrant's Current Report on Form 10-Q filed on November 14, 2014)

3.3		Certificate to Amendment dated May 28, 2021 (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 8-K filed on June 2, 2022)

3.4		Second Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on March 14, 2022)

31.1		Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended

31.2		Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended

32.1		Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *

32.2		Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *

101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Page 29 of 30

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ZIVO BIOSCIENCE, INC.
Date: August 14, 2024

	By:	/s/ John B. Payne
		John B. Payne
		Chief Executive Officer

	By:	/s/ Keith R. Marchiando
		Keith R. Marchiando
		Chief Financial Officer

Page 30 of 30

Get the next $ZIVO alert in real time by email

SEC Form 10-Q filed by Zivo Bioscience Inc.

Chat with this insight

Recent Analyst Ratings for
$ZIVO

$ZIVO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Zivo Bioscience Inc.

SEC Form SC 13D filed by Zivo Bioscience Inc.

SEC Form SC 13D filed by Zivo Bioscience Inc.

$ZIVO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group initiated coverage on Zivo Bioscience with a new price target

$ZIVO
Press Releases

Fastest customizable press release news feed in the world

ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens

Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience's Coccidiosis Treatment in Broiler Chickens

ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study

$ZIVO
SEC Filings

Zivo Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities